The FDA OKs J&J's (JNJ -0.2%) Sirturo drug for treating tuberculosis in patients who don't respond to other medicines. Sirturo is the first drug in four decades to fight TB using a new mechanism - the treatment blocks an enzyme that's vital for the survival of TB bacteria. The FDA authorization comes after only Phase II of trials - J&J is due to start Phase III in Q1 2013 - and despite more patients dying than with other drugs.
The FDA OKs J&J's (JNJ -0.2%) Sirturo drug for treating tuberculosis in patients who don't...
From other sites
Video at CNBC.com (Tue, 5:41PM)
Video at CNBC.com (Thu, 3:53PM)
Video at CNBC.com (Sep 16, 2016)
Video at CNBC.com (Aug 18, 2016)
Video at CNBC.com (Jul 19, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs